| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Aminolevulinic acid (5-ALA) is primarily known for its role as a biosynthetic precursor to heme 5-ALA — 5-aminolevulinic acid (5-aminolevulinic acid; often administered as the hydrochloride salt) is an endogenous, small-molecule heme biosynthesis precursor used clinically as a pro-photosensitizer for tumor visualization and, when paired with an appropriate light source, photodynamic therapy (PDT). It is formally a drug/prodrug modality whose functional identity is to drive intracellular accumulation of the fluorescent porphyrin protoporphyrin IX (PpIX), enabling fluorescence-guided resection (notably high-grade glioma) and light-activated cytotoxicity in appropriately illuminated tissues. Standard abbreviations include 5-ALA, ALA; the key active photochemical mediator is PpIX. Tumor selectivity is primarily metabolic (differential porphyrin/heme pathway handling), rather than target-receptor binding, and clinical performance is strongly constrained by light penetration and local oxygen availability. Primary mechanisms (ranked):
Bioavailability / PK relevance: Route-locked. Oral ALA-HCl is used for intraoperative fluorescence in glioma with timed dosing prior to anesthesia/surgery; topical formulations are used for dermatologic PDT with local incubation followed by office-based illumination. Systemic exposure is clinically relevant for oral use (and photosensitivity risk), while topical use is primarily local with workflow defined by incubation + illumination. In-vitro vs systemic exposure relevance: Many “dark” in-vitro ALA studies use concentrations that are not directly exposure-matched to clinical plasma levels; the clinically dominant cytotoxic mechanism is typically light-triggered, PpIX-mediated photochemistry rather than concentration-only pharmacology. Clinical evidence status: Established clinical deployment as an adjunct optical imaging agent for fluorescence-guided resection of suspected high-grade glioma (approved) and as a photosensitizer precursor for dermatologic PDT (approved for actinic keratosis; additional indications vary by jurisdiction). Oncology PDT applications beyond these settings are heterogeneous and commonly investigational or center-specific. -ALA is used in medical therapies such as photodynamic therapy (PDT) for certain types of cancer and skin conditions.- Inside the cells, ALA enters the heme biosynthetic pathway and is converted to protoporphyrin IX (PpIX), a potent photosensitizer. -The light activates the accumulated PpIX, leading to the production of reactive oxygen species (ROS). -FDA approved June 2017 as a photo-imaging tool during neurosurgery for malignant glioma. The patient takes an oral dose of Gleolan 3 hours before surgery. Mechanistic pathway ranking for 5-ALA (oncology focus)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Source: |
| Type: protein |
| Manganese superoxide dismutase (MnSOD, also known as SOD2). SOD2 (Superoxide Dismutase 2) is a protein that is a member of the superoxide dismutase family of enzymes, which are involved in the detoxification of superoxide radicals. -MnSOD is localized in the mitochondria and plays a key role in detoxifying superoxide radicals, thereby limiting oxidative damage and maintaining mitochondrial integrity. • By modulating ROS levels, MnSOD influences cellular signaling pathways involved in proliferation, apoptosis, and metabolic adaptation—all of which are critical during tumorigenesis. Typically low SOD2 expression in cancers, with poor prognosis. -Increased MnSOD levels may help tumor cells manage the high levels of ROS resulting from rapid cell division and metabolic alterations, which can contribute to tumor progression. - Some prognostic studies associate high levels of MnSOD with resistance to apoptosis and poorer patient outcomes; however, findings are not entirely consistent across all studies. • Depending on the tumor type and the balance with other antioxidant systems, high MnSOD can be associated with either favorable or unfavorable clinical outcomes, reflecting its dual roles in cancer biology. |
| 3453- | 5-ALA, | The heme precursor 5-aminolevulinic acid disrupts the Warburg effect in tumor cells and induces caspase-dependent apoptosis |
| - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:332 Target#:935 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid